Dr. Bradley Receives R01 Grant from NIH
Todd Bradley, PhD, Center for Pediatric Genome Medicine, was recently awarded a five-year, $2.9 million R01 grant from the National Institutes of Health – National Institute of Allergy and Infectious Diseases. Dr. Bradley’s “Natural killer cell regulation of the germinal center HIV neutralizing antibody response” study will determine key molecular pathways that are critical for natural killer (NK) cell immunoregulation of the HIV antibody response and evaluate the effects of modulating these responses in a preclinical HIV vaccine trial in nonhuman primates.
“Developing a safe and effective HIV vaccine is a top global health priority and a key component of a protective vaccine is eliciting antibodies that can neutralize the broad diversity of HIV viral strains,” Dr. Bradley said. “The results of our study will help identify novel NK cell-targeting strategies that can be applied during HIV-1 vaccination to improve immune responses.”
Children’s Mercy Kansas City is ranked as one of “America's Best Children's Hospitals” in nine specialties rated by U.S. News & World Report and has received MagnetTM recognition for excellence in nursing services five consecutive times. With 386 licensed beds and a medical staff of more than 750 pediatric subspecialists, we care for children from all 50 states and from around the world. In addition, our leadership in pediatric genomic medicine and individualized pediatric therapeutics is driving research and innovation in neonatology, nephrology, endocrinology, gastroenterology, neurology, heart, cancer and other subspecialties to transform outcomes for children. Children’s Mercy also is nationally recognized for innovation in psychosocial care and creating a family-centered environment focused on the unique needs of hospitalized children and their families. Our love for children powers everything we do, inspiring our research, innovations and our everyday care. Because love has no limits. And with it, neither do we.